{"id":15535,"date":"2026-06-03T19:17:00","date_gmt":"2026-06-03T17:17:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=ee725a34209b86ead82e3269106e2c5b"},"modified":"2026-06-03T19:17:00","modified_gmt":"2026-06-03T17:17:00","slug":"parnell-adds-sevoflurane-to-its-growing-veterinary-anesthesia-portfolio","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=15535","title":{"rendered":"Parnell Adds Sevoflurane to Its Growing Veterinary Anesthesia Portfolio"},"content":{"rendered":"<p class=\"bwalignc\">\n<b>Parnell now offers a comprehensive anesthesia toolkit from a single, trusted partner<\/b><\/p><p>OVERLAND PARK, Kan.--(BUSINESS WIRE)--Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2818081\/5\/Sevoflurane_-_Bottle_Carton.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2818081\/22\/Sevoflurane_-_Bottle_Carton.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2818081\/5\/Sevoflurane_-_Bottle_Carton.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2818081\/21\/Sevoflurane_-_Bottle_Carton.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2735034\/5\/Parnell_Logo_Blk%26Red_Tagline.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2735034\/22\/Parnell_Logo_Blk%26Red_Tagline.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2735034\/5\/Parnell_Logo_Blk%26Red_Tagline.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260603475010\/en\/2735034\/21\/Parnell_Logo_Blk%26Red_Tagline.jpg\" \/><\/a><p>\nThe addition reinforces Parnell\u2019s commitment to delivering confidence at every stage of the anesthetic protocol. With Sevoflurane joining PropofolVet Multidose, Parnell Brand Dexmedetomidine Hydrochloride Injection, CONTRASED\u2122 (atipamezole hydrochloride), and Isoflurane Inhalation Anesthetic, practices can now source a complete anesthesia toolkit from a single, accountable partner.<\/p><p>\n\u201cVeterinary professionals place immense trust in the products they use during anesthesia, and that responsibility drives everything we do,\u201d said Pablo Lamberto, DVM, U.S. General Manager at Parnell. \u201cIn a category where consistency and reliability matter as much as cost, the addition of Sevoflurane allows us to better support clinics with dependable, high-quality options across the entire anesthesia protocol.\u201d<\/p><p>\n<b>Key Features<\/b><\/p><ul class=\"bwlistdisc\">\n<li>\nIndicated for induction and maintenance of general anesthesia in dogs<\/li>\n<li>\nNonflammable and nonexplosive, supporting a safer clinical environment<\/li>\n<li>\nRapid induction and recovery profile consistent with Sevoflurane's established clinical performance<\/li>\n<li>\nAvailable in 250 mL bottles<\/li>\n<li>\nCompetitively priced to support veterinary practices managing anesthesia costs without compromise<\/li>\n<\/ul><p>\n<b>Supporting the Whole Team<\/b><\/p><p>\nParnell's commitment to veterinary teams extends beyond the product. The Foundations of Anesthesia &amp; Sedation Certificate Program \u2014 an online course offering 10 RACE-approved CE hours \u2014 is designed to build staff competency and confidence in anesthesia protocols. For practices investing in both clinical excellence and team development, the program complements the portfolio as part of a broader support ecosystem. Learn more at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fparnell.com%2Fproducts%2Fpetcare%2Ffoundations-of-anesthesia-sedation-veterinary-certificate&amp;esheet=54543879&amp;newsitemid=20260603475010&amp;lan=en-US&amp;anchor=parnell.com%2Feducation&amp;index=1&amp;md5=8dd0a9d190248b33ff00646f2b607107\" rel=\"nofollow\" shape=\"rect\">parnell.com\/education<\/a>.<\/p><p>\nFor more information about Sevoflurane Inhalation Anesthetic, visit <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fparnell.com%2Fsevoflurane&amp;esheet=54543879&amp;newsitemid=20260603475010&amp;lan=en-US&amp;anchor=parnell.com%2Fsevoflurane&amp;index=2&amp;md5=7573e9e4f1051d10c0c3bc4cc0d74611\" rel=\"nofollow\" shape=\"rect\">parnell.com\/sevoflurane<\/a> or contact your local distributor representative.<\/p><p>\n<b>About Parnell<\/b><\/p><p>\nParnell is a veterinary pharmaceutical company focused on developing, manufacturing, and commercializing animal health solutions across anesthesia and beyond. With a strong commitment to quality and customer partnerships, Parnell manufactures and markets products for companion and production animals in 10 countries. Learn more at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.parnell.com&amp;esheet=54543879&amp;newsitemid=20260603475010&amp;lan=en-US&amp;anchor=www.parnell.com&amp;index=3&amp;md5=2db22d66f47d04268dbd5f4f8b6abe2d\" rel=\"nofollow\" shape=\"rect\">www.parnell.com<\/a>.<\/p><p>\n\u00a92026 Parnell Technologies Pty LTD. CONTRASED is a trademark of Parnell Technologies Pty LTD. MKT-26-083 PC US<\/p><br\/> <b>Contacts<\/b> <br\/><p>\n<b>Media Contact:<\/b><br\/>Angela Kille\n<br\/>Associate Director of Strategic Marketing\n<br\/><a  href=\"mailto:angela.kille@parnell.com\" rel=\"nofollow\" shape=\"rect\">angela.kille@parnell.com<\/a><br\/>913\u2011274\u20112100<\/p>","protected":false},"excerpt":{"rendered":"<p>Parnell now offers a comprehensive anesthesia toolkit from a single, trusted partnerOVERLAND PARK, Kan.&#8211;(BUSINESS WIRE)&#8211;Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support vet&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-15535","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15535"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15535\/revisions"}],"predecessor-version":[{"id":15536,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/15535\/revisions\/15536"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}